In this paper, we provide some topological criteria for the Poisson Dixmier-Moeglin equivalence for $A$ in terms of the poset $({ m P. spec A}, subseteq)$ and the symplectic leaf or core stratification on its maximal spectrum. In particular, we prove that the Zariski topology of the Poisson prime spectrum and of each symplectic leaf or core can detect the Poisson Dixmier-Moeglin equivalence for any complex affine Poisson algebra. Moreover, we generalize the weaker version of the Poisson Dixmier-Moeglin equivalence for a complex affine Poisson algebra proved in [J. Bell, S. Launois, O.L. S'anchez, and B. Moosa, Poisson algebras via model theory and differential algebraic geometry, J. Eur. Math. Soc. (JEMS), 19(2017), no. 7, 2019-2049] to the general context of a commutative differential algebra.

We study an equivariant extension of the Batalin-Vilkovisky formalism for quantizing gauge theories. Namely, we introduce a general framework to encompass failures of the quantum master equation, and we apply it to the natural equivariant extension of AKSZ solutions of the classical master equation (CME). As examples of the construction, we recover the equivariant extension of supersymmetric Yang-Mills in 2d and of Donaldson-Witten theory.

In cite{S 2017}, Suh gave a non-existence theorem for Hopf real hypersurfaces in the complex quadric with parallel normal Jacobi operator. Motivated by this result, in this paper, we introduce some generalized conditions named $mathcal C$-parallel or Reeb parallel normal Jacobi operators. By using such weaker parallelisms of normal Jacobi operator, first we can assert a non-existence theorem of Hopf real hypersurfaces with $mathcal C$-parallel normal Jacobi operator in the complex quadric $Q^{m}$, $m geq 3$. Next, we prove that a Hopf real hypersurface has Reeb parallel normal Jacobi operator if and only if it has an $mathfrak A$-isotropic singular normal vector field.

In this paper we construct an equivariant embedding of the affine space $mathbb{A}^n$ with the translation group action into a complete non-projective algebraic variety $X$ for all $n geq 3$. The theory of toric varieties is used as the main tool for this construction. In the case of $n = 3$ we describe the orbit structure on the variety $X$.

The global health threat from COVID-19 has been controlled in a number of instances by large-scale testing and contact tracing efforts. We created this document to suggest three functionalities on how we might best harness computing technologies to supporting the goals of public health organizations in minimizing morbidity and mortality associated with the spread of COVID-19, while protecting the civil liberties of individuals. In particular, this work advocates for a third-party free approach to assisted mobile contact tracing, because such an approach mitigates the security and privacy risks of requiring a trusted third party. We also explicitly consider the inferential risks involved in any contract tracing system, where any alert to a user could itself give rise to de-anonymizing information.

More generally, we hope to participate in bringing together colleagues in industry, academia, and civil society to discuss and converge on ideas around a critical issue rising with attempts to mitigate the COVID-19 pandemic.

The apps and devices you use are conducting surveillance with your every move Sure, you lock your home, and you probably don't share your deepest secrets with random strangers.…

This is normally the time of year when we're up to our eyeballs in concert announcements, but in these topsy-turvy times, we're instead having to write about all the concerts being canceled due to COVID-19. It's a real bummer.…

Every spring, audiences in Moscow are typically congregating for the Kino Short Film Festival, an evening of shorts made by the University of Idaho's senior film students. Things being as they are, the Kenworthy Theater won't be open for this year's event, but the U of I will be streaming a virtual version this Friday, May 8, at 6 pm.…

Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.

Borazine derivatives are used in the manufacture of electronic devices, in particular electroluminescent and semiconductor devices. More specifically, stable borazine derivatives include boron atoms substituted by aryl groups used in one or more layers of an electroluminescent or a semiconductor device, in particular in the emissive layer of organic light-emitting devices (OLED).

A computer-implemented method is provided for statistical data learning under privacy constraints. The method includes: receiving, by a processor, a plurality of pieces of statistical information relating to a statistical object and aggregating, by the processor, the plurality of pieces of statistical information so as to provide an estimation of the statistical object. Each piece of statistical information includes an uncertainty variable, the uncertainty variable being a value determined from a function having a predetermined mean. The number of pieces of statistical information aggregated is proportional to the reliability of the estimation of the statistical object.

The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative.

An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.

Novel compounds of formula (1) wherein: A is especially a linear or branched divalent alkylene radical having between 1 and 10 carbon atoms, and Y is especially a hydrogen atom.

The present invention provides: an uracil derivative represented by general formula (I) or a physiologically acceptable salt thereof (in the formula, R1 represents a hydrogen atom, a C1-10 alkyl group, a C2-6 alkene group or a 3- to 6-membered saturated or 4- to 6-membered unsaturated aliphatic ring group which may contain 1 to 2 hetero atoms independently selected from the group consisting of N, O and S; R2 represents a hydrogen atom, a halogen atom, a cyano group, —NRcRd, —N═CHN(CH3)2, or an C1-3 alkyl group; Ar1 and Ar2 independently represent a 5- to 6-membered aromatic ring group which may contain 1 to 3 hetero atoms independently selected from the group consisting of N, O and S; and L represents a 6-membered aromatic ring group which may contain 1 to 4 nitrogen atoms, a pyrazole group, a triazole group, or an imidazole group); and a therapeutic agent or prophylactic agent for various inflammatory diseases associated with elastase, comprises the compound or the like as an active ingredient.

[Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases.[Means of Solving the Problem]A compound of Formula (1): (where n is 0 to 2; p is 0 to 4; h is 0 to 3; j is 0 to 3; k is 0 to 2; a ring B is an aryl group or a heteroaryl group; X is O, S, or —NR7—; J1 is —CR11aR11b— or —NR11c—; J2 is —CR12aR12b— or —NR12c—; and R1 to R12c are specific groups),a salt of the compound, or a solvate of the salt or the compound.

The present application describes modulators of MCP-1 or CCR-2 of formula or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, n, W, X, R1 and R6, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.

The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group,W is a group of formula —NH—SO2—R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

The invention relates to oxazolopyrimidine compounds of formula I, where A, R1 and R2 are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5alkylR3, wherein R3 is piperidinyl-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkenylR3, wherein R3 is as defined herein; 3) C2-5alkynylR3, wherein R3 is as defined herein; and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation; pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention provides a compound useful as an agent for the prevention or treatment of a sex hormone-dependent disease or the like. That is, the present invention provides a fused heterocyclic derivative represented by the following general formula (I), a pharmaceutical composition containing the same, a medicinal use thereof and the like. In the formula (I), ring A represents 5-membered cyclic unsaturated hydrocarbon or 5-membered heteroaryl; RA represents halogen, alkyl, alkenyl, alkynyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl or the like ; ring B represents aryl or heteroaryl; RB represents halogen, alkyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl or the like; E1 and E2 represent an oxygen atom or the like; U represents a single bond or alkylene; X represents a group represented by Y, —SO2—Y, —O—(alkylene)—Y, —O—Z in which Y represents Z, amino or the like; Z represents cycloalkyl, heterocycloalkyl, aryl, heteroaryl or the like; or the like.

A rubber composition for manufacturing tyres is based on one or more diene elastomers, one or more reinforcing fillers, and a vulcanization system. The vulcanization system includes one or more 1,2,4-triazine compounds chosen from compounds of formula I and compounds of formula II: Certain specific 1,2,4-triazine derivatives are described.

Beta-lactamase inhibiting compounds of the formula ##STR1## or a pharmaceutically acceptable acid addition or carboxylate salt thereof; where n is zero, 1 or 2; X3 is H or Br, R1 is H, the residue of certain carboxy-protecting groups or the residue of an ester group readily hydrolyzable in vivo; one of R12 and R13 is H and the other is vinyl, certain aryl, alkylthio, alkylsulfonyl or certain heterocyclyl, aminomethyl, thiocarboxyamido or amidino groups; one of R2 and R3 is H and the other is as disclosed for the other of R12 and R13, or is Cl or CH2 OH, and R18 is H or certain acyl groups; intermediates useful in their production, methods for their preparation and use, and pharmaceutical compositions containing them.

1,4-Dihydropyridine-3-carboxylate derivatives are produced having vasodilating and hypotensive action.

Herbicidally active 5-amino-1-phenyl-pyrazoles, most of which are new, of the formula ##STR1##

Antivirally active compounds of formula (I), wherein R1 is hydrogen, hydroxy, mercapto or amino; R2 is hydrogen, hydroxy, fluoro, chloro or amino; R3 and R4 are independently selected from (II), (III), amino, hydroxy or an ether or ester residue thereof, or R3 together with R4 is (IV), wherein M is hydrogen or a pharmaceutically acceptable counterion; and n is 1 or 2; with the proviso that, when R2 is amino and R3 and R4 are hydroxy, R1 is not hydroxy and in addition, when n=1, R1 is not hydrogen, and pharmaceutically acceptable salts thereof; processes for preparation of said compounds, a pharmaceutical composition comprising said compounds, methods for treatments of virus infections as well as use of compounds of formula (I) without the proviso for the manufacture of a medicament for treatment of AIDS. ##STR1##

A method of producing a bis(2-carboxyethyl)-alkyl phosphine oxide represented by the following general formula (1) is disclosed. ##STR1## The method comprises the following Steps 1-4: step 1 wherein phosphine is reacted with acrylonitrile to produce bis(2-cyanoethyl)phosphine and then, in step 2, reacted with an alkene to produce a bis(2-cyanoethyl)alkyl phosphine, and in step 3, reacted with an oxidizing agent to produce a bis(2-cyanoethyl)alkyl phosphine oxide, and in step 4, said bis(2-cyanoethyl)alkyl phosphine oxide is reacted with water or a lower alcohol to give a bis(2-carboxyethyl)alkyl phosphine oxide or a derivative thereof.

This invention relates to the oligomerization of olefinic compounds in the presence of an activated oligomerization catalyst. The invention also extends to a particular manner for providing an activated oligomerization catalyst. According to the present invention, there is provided a process for producing an oligomeric product by the oligomerization of at least one olefinic compound, the process including (a) providing an activated oligomerization catalyst by combining, in any order, iii) a source of chromium, ιv) a ligating compound of the formula (R1)mX1(Y)X2(R2)n wherein X1 and X2 are independently an atom selected from the group consisting of nitrogen, phosphorus, arsenic, antimony, bismuth, oxygen, sulphur and selenium or said atom oxidized by S, Se, N or O where the valence of X1 and/or X2 allows for such oxidation, Y is a linking group between X1 and X2 which linking group contains at least one nitrogen atom which is directly bonded to X1 or X2, m and n are independently 0, 1 or a larger integer, and R1 and R2 are independently hydrogen, a hydrocarbyl group, an organoheteryl group or a heterohydrocarbyl group, and the respective R1 groups are the same or different when m>1, and the respective R2 groups are the same or different when n>1, in) a catalyst activator which is an organoboron compound including a cation and a non-coordinating anion of the general formula [(R10)xL*-H]+[B(R20)4]− wherein L* is an atom selected from the group consisting of N, S and P, the cation [(R10)x L*-H]* is a Bronsted acid, x is an integer 1, 2 or 3, each R10 is the same or different when x is 2 or 3 and each is a —H, hydrocarbyl group or a heterohydrocarbyl group, provided that at least one of R10 comprises at least 6 carbon atoms and provided further that the total number of carbon atoms in (R10)x collectively is greater than 12, R20 independently at each occurrence is selected from the group consisting of hydride, dialkylamido, halide, alkoxide, aryloxide, hydrocarbyl, halosubstituted-hydrocarbyl radicals, halosubstituted-alkoxide, halosubstituted-aryloxide and a halosubstituted aromatic ring moiety with at least one halide substituent on the aromatic ring, and vi) an aliphatic solvent, and (b) contacting the at least one olefinic compound with the activated oligomerization catalyst to produce an oligomeric product.

A durable ambient light curable waterproof liquid rubber coating with volatile organic compound (VOC) content of less than 450 grams per liter made from ethylene propylene diene terpolymer (EPDM) in a solvent, a photoinitiator, an additive, pigments, and fillers, and a co-agent and a method for making the formulation, wherein the formulation is devoid of thermally activated accelerators.

This invention provides a method related to the preparation of derivatives of poly(ethylene glycol), wherein the method comprises increasing the pH of an aqueous composition comprising a poly(ethylene glycol) bearing a —O—(CH2)n—CO2R3 functional group to result in an aqueous composition comprising a poly(ethylene glycol) bearing a —O—(CH2)n—CO2H functional group, wherein R3 is alkyl and (n) in each instance is 1-6.

A technique for activating processor cores within a computer system is disclosed. Initially, a value representing a number of processor cores to be enabled within the computer system is received. The computer system includes multiple processors, and each of the processors includes multiple processor cores. Next, a scale variable value representing a specific type of tasks to be optimized during an execution of the tasks within the computer system is received. From a pool of available processor cores within the computer system, a subset of processor cores can be selected for activation. The subset of processor cores is activated in order to achieve system optimization during an execution of the tasks.

A method for activating processor cores within a computer system is disclosed. Initially, a value representing a number of processor cores to be enabled within the computer system is received. The computer system includes multiple processors, and each of the processors includes multiple processor cores. Next, a scale variable value representing a specific type of tasks to be optimized during an execution of the tasks within the computer system is received. From a pool of available processor cores within the computer system, a subset of processor cores can be selected for activation. The subset of processor cores is activated in order to achieve system optimization during an execution of the tasks.

The invention relates to a method of use of certain derivatives of formula (I) in the form of any one of its stereoisomers or a mixture thereof, and wherein R1 represents a hydrogen atom, a C1-4 alkyl or alkenyl group, or a (CHR)2OH group, each R being a hydrogen atom or a methyl group; R2 represents a hydrogen atom or a methyl, ethyl or n-propyl group; and R3 represents a hydrogen atom or a methyl group, as perfuming ingredients. The present invention concerns also certain compounds and compositions or articles containing such compounds.

The present invention relates to compounds of formula (I) in the form of any one of its stereoisomers or a mixture thereof, and wherein R1 represents a substituent of the benzene ring and is a bromine atom or a linear, branched or cyclic C1-8 alkyl, alkenyl, alkoxy or alkenyloxy group; R2 represents a C1-3 alkyl group; and R3 represents a hydrogen atom or a methyl or ethyl group; and their use as perfuming ingredients, for instance to impart odor notes of the watery/ozone type.

1-(3/4-isobutyl-1/6-methylcyclohex-3-enyl)methanols and derivatives thereof having appreciable floral and hesperidic odor notes, their use as fragrance ingredient and perfumed products comprising them.

The present invention relates to novel pyrimidine derivatives and their use in perfume compositions. The novel pyrimidine derivatives of the present invention are represented by the following formula: wherein m and n are integers of 0 or 1, with the proviso that when m is 0, n is 1 and when m is 1, n is 0; andwherein the dashed circle represents either single or double bonds.

A method for cultivating Monarda fistulosaincludes planting seeds at rates between about 2.5 and about 5 pounds per acre, preferably about 4 pounds per acre. Fuel costs are reduced because seeding, mowing the first season, and harvesting in seasons thereafter are all that is required. Reduction in herbicide use results from the heavy rate of planting, improved germination attributed to rolling, and the plant's natural herbicides which are more highly effective when seeded at the higher rate. The method includes seeding, mowing during a first growing season, and harvesting each season thereafter. This method results in oil without weed contamination and carvacrol levels are high.

A system, method, and computer program product for automatically generating equivalent assertions in different forms for different verification tools, which may be analog or digital. A user submits a set of logic assertions that, if unclocked, are converted to clocked assertions by generating and skewing clocks to ensure simulator uniformity. A stimulus is generated, perhaps at random, or input. A test bench is either input or synthesized. For each verification tool, the test bench is simulated and simulation results are captured. An assertion status difference engine evaluates result differences between the verification tools, and identifies and outputs differences indicating a significant inconsistency. Errors in verification tool implementation and user assertion coding can be detected. The simulators used may include SPICE and Verilog, or any other simulators that differ in type, simulation algorithm, input format, or vendor implementation.

In a mobile device, a bone conduction or vibration sensor is used to detect the user's speech and the resulting output is used as the source for a low power Voice Trigger (VT) circuit that can activate the Automatic Speech Recognition (ASR) of the host device. This invention is applicable to mobile devices such as wearable computers with head mounted displays, mobile phones and wireless headsets and headphones which use speech recognition for the entering of input commands and control. The speech sensor can be a bone conduction microphone used to detect sound vibrations in the skull, or a vibration sensor, used to detect sound pressure vibrations from the user's speech. This VT circuit can be independent of any audio components of the host device and can therefore be designed to consume ultra-low power. Hence, this VT circuit can be active when the host device is in a sleeping state and can be used to wake the host device on detection of speech from the user. This VT circuit will be resistant to outside noise and react solely to the user's voice.

Provided is an efficient technology for synthesizing diamino acids (diamino acid derivatives). Disclosed is a manufacturing method for diamino acid derivatives wherein the fluorenyl groups of the diamino acid derivative starting materials represented by General Formula [II] or [IV] are removed.

This invention relates to novel precursors suitable for 18F radiolabeling of glutamate derivatives, methods for preparing such compounds and its intermediates, compositions comprising such compounds, kits comprising such compounds or compositions and methods for 18F radiolabeling of glutamate derivatives wherein the obtained 18F radiolabeled glutamate derivatives are suitable for diagnostic imaging by Positron Emission Tomography (PET) of proliferative diseases e.g. tumor in mammals.

The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.

The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.

A recombinant micro-organism producing resveratrol by a pathway in which phenylalanine ammonia lyase (PAL) produces trans-cinnamic acid from phenylalanine, cinnamate 4-hydroxylase (C4H) produces 4-coumaric acid from said trans-cinnamic acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA, or in which L-phenylalanine- or tyrosine-ammonia lyase (PAL/TAL) produces 4-coumaric acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA. The micro-organism may be a yeast, fungus or bacterium including Saccharomyces cerevisiae, E. coli, Lactococcus lactis, Aspergillus niger, or Aspergillus oryzae.

The present invention relates to novel 1,2,3-triazolyl purine derivatives. The invention also relates to using the derivatives to treat cancer and various viral infections. An example of a 1,2,3-triazolyl purine derivative of the invention is

A biometric monitoring device measuring various biometric information is provided that allows the person to take and/or display a heart rate reading by a simple user interaction with the device, e.g., by simply touching a heart rate sensor surface area or moving the device in a defined motion pattern. Some embodiments of this disclosure provide biometric monitoring devices that allow a person to get a quick heart rate reading without removing the device or interrupting their other activities. Some embodiments provide heart rate monitoring with other desirable features such as feedback on data acquisition status.

The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile.

A feed additive includes at least one of p-thymol, a salt derivative and an ester derivative thereof for animals.

The present invention provides drug conjugates comprising 5-aminolevulinic acid (ALA), an aldehyde and a carboxylic acid that may function as a histone deacetylase inhibitor (HDACI). These conjugates may serve as co-drugs which release a plurality of active species in vivo. The novel drug conjugates may be used, for the treatment or prevention of cancer in PDT-dependent and/or PDT-independent (nonPDT) treatments, as well as for cosmetic uses. In addition the present invention provides novel uses for both the novel and known compounds. According to some embodiments, the present invention provides drug conjugates (co-drugs) comprising (i) ALA, (ii) an aldehyde and (iii) a carboxylic acid that may function as a histone deacetylase inhibitor (HDACO for the treatment of anemia and/or for the induction of erythropoiesis.